News

Who will make the generic version of Lipitor? (Morning Read)

Current medical news from today including: Questions over the generic future of Lipitor, the dirty little secret of biotech IPOs and good news for health nonprofits.

Current medical news and unique business news for anyone who cares about the healthcare industry.

The war over Lipitor: Indian generics maker Ranbaxy was expected to be the first generic manufacturer of Pfizer’s wildly successful cholesterol-fighting drug Lipitor. Now it’s not a sure thing. After the FDA accused the company of  “fraudulent conduct,” generic drugmakers “are now feuding like greedy relatives at Lipitor’s graveside as they wait to see whether Ranbaxy will maintain its status as front-runner.”

The dirty little secret of biotech IPOs: It’s that insiders such as VCs are having to buy into biotech IPOs in order to get the deals priced, something far less common in tech IPOs. The trend is yet another affirmation that biotech IPOs are just financing events, and tough ones at that, Forbes says.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Artificial pancreas update: A team led by researchers from University of Cambridge showed that closed loop insulin delivery was effective in controlling overnight blood glucose levels in patients with type 1 diabetes.

Good days for health nonprofits: After a recession-caused drop, donations to healthcare nonprofits are headed back up again, according to two new reports.

Taller is better: Is the growth in human height over the last couple hundred years “the most significant development in humanity’s long history”? A Nobel-prize-winning economist thinks so.

A little regulatory humor from the Onion: “Pfizer Breaks Psychological Need To Always Seek FDA’s Approval

Topics